R eactive oxygen species (ROS) such as superoxide (O 2
Ϫ· ) and hydrogen peroxide (H 2 O 2 ) play important roles in regulating normal vascular function. 1, 2 Although ROS generally cause an increase in vascular tone via inactivation of endothelium-derived nitric oxide (NO), in cerebral microvessels ROS can decrease artery tone under physiological conditions. 3 Specifically, H 2 O 2 has been shown to activate large-conductance calcium-activated K ϩ (BK Ca ) channels in cerebral arteries, leading to hyperpolarization and vasodilatation. 4 Chronic hypertension is associated with a number of alterations to cerebral artery function and structure 5 and increased vascular ROS generation in systemic blood vessels. 6 However, there is presently no information regarding whether ROS levels are higher in cerebral vessels during hypertension and, if so, how this may affect regulation of cerebrovascular tone.
NADPH-oxidases are a major enzymatic source of ROS in the systemic vasculature and are present in all major cell types that make up the vessel wall (ie, endothelial cells, smooth muscle cells, and adventitial fibroblasts). 7 These enzymes transfer electrons to molecular O 2 via a flavincontaining subunit, the identity of which varies between isoforms. In different types of vascular cells, gp91phox and the homologues Nox1 and Nox4 have been identified as electron-transferring subunits. 8 In cerebral arteries, NADPH-and NADH-induced production of ROS are reported to be mediated by a flavin-containing enzyme, most likely NADPH-oxidase. 9 Moreover, activation of this enzyme was associated with dilatation of cerebral vessels in vitro and in vivo. 9 There is no information available on the role of this enzyme in cerebral vessels during pathophysiological conditions. The present study tested the hypothesis that activation of NADPH-oxidase in cerebral blood vessels causes H 2 O 2 -mediated opening of BK Ca channels, leading to cerebral vasodilatation in vivo. Fur-thermore, we examined whether chronic hypertension affects the activity, function, and molecular expression of NADPH-oxidase in cerebral arteries.
Materials and Methods
All procedures were approved by the institutional animal ethics committee. In total, 80 male Wistar-Kyoto rats (WKY) (weight, 332Ϯ12 g; mean arterial pressureϭ92Ϯ2 mm Hg) and 54 male spontaneously hypertensive rats (SHR) (weight, 460Ϯ22 g; mean arterial pressureϭ165Ϯ6 mm Hg) up to 10 months old were studied. In specific experimental subgroups in which comparisons were made between WKY and SHR, rats from the 2 strains were age matched.
Measurement of O 2
؊· Production by Isolated Cerebral Arteries WKY (nϭ9) and SHR (nϭ11) were anesthetized by inhalation of 80% CO 2 /20% O 2 and killed by decapitation. Basilar arteries were excised and cut into two 5-mm ring segments, and O 2 Ϫ· production was then measured by 5 mol/L lucigenin-enhanced chemiluminescence as described previously. 10 
Measurement of Cerebral Artery Diameter In Vivo
WKY (nϭ47) and SHR (nϭ19) were anesthetized with pentobarbital sodium (50 mg/kg IP). Supplemental pentobarbital was administered via a femoral vein cannula (10 to 20 mg/kg per hour). Blood gases were monitored and adjusted (pH 7.39Ϯ0.01, PCO 2 ϭ37Ϯ1 mm Hg, PO 2 ϭ162Ϯ12 mm Hg) throughout each experiment. As described previously, 11 a craniotomy was performed over the ventral brain stem, the basilar artery was exposed, and the cranial window was superfused with artificial cerebrospinal fluid at 2 mL/min. Cerebrospinal fluid sampled from the cranial window had the following pH and gases: pH 7.44Ϯ0.01, PCO 2 ϭ31Ϯ1 mm Hg, PO 2 ϭ136Ϯ1 mm Hg. Basilar artery diameter was monitored with a microscope coupled to a video monitor and measured with a computer-based tracking program (Diamtrak, Montech).
In Vivo Protocol
After surgical preparation, a 20-minute stabilization period was allowed before topical application of drugs. Artery diameter was measured under baseline conditions and again when responses to drugs were stable. A 15-to 20-minute period was allowed between applications of vasodilators. Vascular responses were expressed as percent change in artery diameter compared with baseline.
Responses of the basilar artery to the following agonists were investigated: NADPH (10 and 100 mol/L), H 2 O 2 (100 and 300 mol/L), sodium nitroprusside (SNP) (10 and 100 nmol/L), papaverine (10 and 100 mol/L), and aprikalim (10 and 30 mol/L). Responses were examined in the absence and presence of diphenyle-
In all experiments, control responses to each agonist were obtained before topical application of inhibitor drugs. After 20-minute treatment with 1 of these inhibitors, responses to vasoactive agents were reexamined in the continued presence of the inhibitor. Only 1 inhibitor was investigated per animal.
Reverse Transcription Reaction
For each mRNA sample, basilar arteries were pooled from 3 WKY or 3 SHR, and total RNA was extracted with the use of a commercially available kit (SV Total RNA Isolation System, Promega) and quantified spectrophotometrically (absorbance at 260 nm). Total RNA was subsequently used for reverse transcription (RT) in a final reaction volume of 100 L as described previously. 10 
Real-Time Polymerase Chain Reaction
Real-time polymerase chain reaction (PCR) and the ⌬⌬Ct method were used as previously described to examine mRNA expression of the NADPH-oxidase subunits (gp91phox, Nox1, Nox4, p22phox, p47phox) and Cu 2ϩ /Zn 2ϩ -superoxide dismutase (SOD), relative to a "reference" sample, in basilar arteries from WKY and SHR. 10, 12 Primers and probes for target genes were designed with the use of Primer Express software (PE Biosystems) and the published mRNA sequences (Table, available online at http://stroke.ahajournals.org). 18S rRNA was used as an internal standard and was measured with the use of commercially available primers and probe (PE Biosystems; Table, available online at http://stroke.ahajournals.org). Probes were labeled at the 5Ј end with the fluorescent dyes FAM (for target genes) and VIC (for 18S) and at the 3Ј end with the quencher molecule TAMRA. 12 Drugs H 2 O 2 was obtained from Merck, and all other drugs were from Sigma. DPI was prepared at 10 mmol/L in dimethyl sulfoxide and diluted in saline (in vivo experiments) or Krebs-HEPES (in vitro experiments) such that the final concentration of dimethyl sulfoxide was Յ0.05%. All other drugs were dissolved and diluted in saline or Krebs-HEPES as appropriate.
Data Analysis
All results are expressed as meanϮSEM. Statistical comparisons were made with the use of Student's paired or unpaired t tests or ANOVA as appropriate. A value of PϽ0.05 was considered significant.
Results
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Cerebral Vasodilatation In Vivo
NADPH (10 and 100 mol/L) elicited concentrationdependent dilatation of the basilar artery in WKY ( Figure  3a and 3b). In most animals (approximately 70%), NADPH elicited a transient peak dilatation at either or both concentrations, followed by a sustained steady state response (Figure 3a) . Peak responses to 10 and 100 mol/L NADPH were 16Ϯ4% (nϭ10) and 29Ϯ3% (nϭ23), respectively. However, since this peak response did not occur in all animals, we have focused on the steady state responses that were reproducible within the same animal (time control steady state responses to 10 and 100 mol/L NADPH in WKY: firstϭ8Ϯ2% and 17Ϯ6%; secondϭ8Ϯ1% and 14Ϯ1%; nϭ4). Overall, steady state responses to 10 and 100 mol/L NADPH in WKY were 7Ϯ1% and 13Ϯ1% (nϭ30), respectively. 
NADPH-Induced Vasodilatation Is Enhanced in Hypertension
NADPH-induced vasodilatation was approximately 70% greater in age-matched SHR (24Ϯ2 weeks; nϭ9) than WKY (24Ϯ1 weeks; nϭ18; Figure 3b ). This enhancement was selective for NADPH since responses to SNP were similar in WKY and SHR (Figure 3c ). (Figure 4a ) and SHR (not shown), without affecting responses to a nonspecific vasodilator, papaverine (Figure 4b ), or an endothelial NO-dependent vasodilator, acetylcholine (Figure 4c ). Combined treatment of the cranial window with N-nitro-Larginine methyl ester (30 mol/L) and indomethacin (10 mol/L) had no effect on responses to NADPH but abolished vasodilatation to acetylcholine (nϭ6; data not shown), confirming no contribution of NO synthase or cyclooxygenase to the response to NADPH.
NADPH-Induced Vasodilation
We next tested whether vasodilator responses to NADPH may be mediated by endogenous H 2 O 2 . First, we established that exogenous H 2 O 2 elicits concentration-dependent dilatation of the basilar artery, which was reproducible within the same animal (time control responses to 100 and 300 mol/L H 2 O 2 in WKY: firstϭ9Ϯ3% and 31Ϯ12%; secondϭ9Ϯ6% and 31Ϯ7%; nϭ3). Second, we found that catalase (1000 U/mL) inhibited vasodilatation to both NADPH (Figure 5a arteries from SHR versus WKY, and this was associated with greater NADPH-oxidase-dependent O 2 Ϫ· production and vasodilatation in SHR. To our knowledge this is the first study to demonstrate a functional consequence of increased vascular expression and activity of a Nox4-containing NADPHoxidase in chronic hypertension.
NADPH-Oxidase Activity and Expression in Cerebral Vessels
It is well established that NADPH-oxidase is a major source of ROS in the systemic vasculature and that its activity is upregulated in pathophysiological states such as hypertension. 7 Although we were unable to detect O 2 Ϫ· in isolated basilar arteries from WKY under basal conditions, ex vivo treatment with NADPH caused a marked increase in O 2 Ϫ· generation. Furthermore, NADPH-stimulated O 2 Ϫ· production was inhibited by DPI, indicating an involvement of NADPHoxidase. Messenger RNA for Nox4, gp91phox, Nox1, p22phox, and p47phox was found to be present in the WKY basilar artery. Thus, together with recent findings by others, 9 there is now strong evidence that NADPH-oxidase is expressed and functional in cerebral blood vessels. Moreover, our present findings strongly suggest that activity of NADPH-oxidase is augmented in cerebral arteries during chronic hypertension. Inactivation of endogenous Cu 2ϩ /Zn 2ϩ -SOD with DETCA not only unmasked a small basal O 2 Ϫ· signal in basilar arteries from some SHR but also revealed that NADPH-stimulated O 2 Ϫ· production was 2.3-fold higher in these tissues than in those from age-matched WKY.
Our finding that higher O 2 Ϫ· production in cerebral arteries from SHR versus WKY was only observed after DETCA treatment suggests that 
Functional Consequences of NADPH-Oxidase Activity in Cerebral Arteries
In the systemic vasculature, ROS generally cause vasoconstriction, mainly via the O 2 Ϫ· -mediated inactivation of endothelial NO. 15, 16 In contrast, a number of ROS have been reported to dilate cerebral arteries. 3 In particular, both exogenous and endogenous H 2 O 2 dilate rat cerebral arterioles in vivo via activation of BK Ca channels. 4, 17 Having first confirmed that exogenous H 2 O 2 similarly dilates the rat basilar artery, we tested whether activation of NADPH-oxidase elicits vasodilatation and, if so, whether this effect is ultimately mediated via the generation of H 2 O 2 and activation of BK Ca channels. In support of this proposal, NADPH elicited dilator responses of the basilar artery in vivo that were sensitive to treatment with the NADPH-oxidase inhibitor DPI at a concentration that did not affect responses to the NO synthase-dependent vasodilator acetylcholine. Vasodilator responses to NADPH were also inhibited by the H 2 O 2 scavenger catalase and the inhibitor of BK Ca channels TEA. Furthermore, NADPH-induced vasodilatation could also be inhibited by the Cu 2ϩ /Zn 2ϩ -SOD inhibitor DETCA, suggesting that SOD activity is required to generate H 2 O 2 at a sufficient rate from NADPH-oxidase-derived O 2 Ϫ· to enable accumulation of H 2 O 2 and decreased vascular tone. Interestingly, none of these inhibitor treatments had any significant effect on baseline diameter of the normotensive WKY basilar artery, suggesting that NADPH-oxidase activation may not play a major role in regulating basal cerebral artery tone under physiological conditions. Chronic hypertension is a major risk factor for stroke. We found that vasodilatation in response to NADPH was significantly greater in chronically hypertensive rats than in agematched normotensive controls. It is unclear what consequences (beneficial or detrimental) higher activity of NADPH-oxidase may have for the regulation of cerebral vascular tone during hypertension. However, ROS-mediated vasodilatation, which appears to represent a physiological mechanism in cerebral vessels during normotension, 4,17 could be beneficial in hypertension by maintaining cerebral blood flow, particularly during cerebral ischemic episodes common in stroke. Evidence from the present study consistent with such a protective effect is that DPI and catalase each constricted the basilar artery of SHR but not WKY. In further support of a protective role for NADPH-oxidase in the cerebral circulation is the recent finding that in a Japanese population, the C242T polymorphism of p22phox is a novel risk factor for ischemic cerebrovascular disease. 18 In a sepa- rate study, Guzik et al 19 found that the C242T polymorphism is independently associated with decreased NADPH-oxidase activity. Taken together, our findings and these recent epidemiological data are compatible with an important protective role for NADPH-oxidase in the cerebral circulation.
Increased Cerebral Artery Nox4 Expression in Hypertension
To shed some light on which isoform of NADPH-oxidase is involved in augmented cerebrovascular O 2 Ϫ· production in hypertension, we measured mRNA expression of gp91phox and the putative vascular homologues of this catalytic subunit, Nox1 and Nox4. Interestingly, while levels of gp91phox and Nox1 were not different, expression of Nox4 was markedly higher in basilar arteries from SHR. This finding is somewhat at odds with previous studies examining the effects of pathophysiological stimuli on Nox4 expression. For example, in vitro treatment of rat aortic smooth muscle cells with angiotensin II downregulates Nox4 expression, 8 while in aortas of renin-overexpressing 20 or angiotensin II-treated 21 hypertensive rats, Nox4 mRNA levels were only modestly higher (ie, Ͻ70%) than in normotensive controls. Indeed, we too found that aortic expression of Nox4 was unaltered in SHR (not shown), which may suggest that this subunit is selectively upregulated in certain vascular beds under pathophysiological conditions to act as a protective mechanism against reduced blood flow.
In summary, this study demonstrates that activation of NADPH-oxidase in cerebral arteries in vivo causes vasodilatation via the generation of H 2 O 2 and opening of BK Ca channels. Importantly, during chronic hypertension NADPHoxidase activity is elevated in cerebral vessels, and this is presumably the result of increased expression of the catalytic subunit Nox4. The functional consequence of this is enhanced vasodilator responses on activation of the enzyme in vivo. It is presently unclear whether the consequences of increased NADPH-oxidase activity in the cerebral circulation are likely to be mainly beneficial or detrimental. However, if it were beneficial, caution should be taken in future attempts to inhibit effects of ROS in systemic vascular diseases so as not to inadvertently compromise cerebral blood flow.
